States seek to lower drug prices by targeting the companies that manage them for health plans

States are increasingly focusing on pharmaceutical middlemen to tackle the issue of high prescription costs. These companies, known as pharmacy benefit managers, play a key role in negotiating drug prices for health insurers, and now legislators are pushing for reforms to bring these negotiations more under state control. The move could lead to significant savings for consumers and is seen as a crucial step in addressing the broader issue of healthcare affordability. This shift underscores a growing frustration with the pharmaceutical industry's pricing practices and the need for more transparent and fair negotiation processes.